BUZZ-India's Gland Pharma rises after US FDA approval for drug application

Reuters01-08

** Shares of Gland Pharma GLAD.NS rise as much as 4.8% 1,790.4 rupees** Pharma co gets approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis** Stock last up 1.7%; top pct gainer on the Nifty Pharma index .NIPHARM, which is down 0.6%** More than 419,000 shares traded, 3.8x the 30-day moving avg** Mean rating of stock is "hold"; their median PT is 2,050 rupees - data compiled by LSEG** GLAD fell 3.2% in 2025

(Reporting by Meenakshi Maidas in Bengaluru)

((meenakshi.maidas@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601334147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 12:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601334147","market":"nz","top_or_hot":-1,"title":"BUZZ-India's Gland Pharma rises after US FDA approval for drug application","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-India's Gland Pharma rises after US FDA approval for drug application</title></head><body><p>** Shares of Gland Pharma <span>GLAD.NS</span> rise as much as 4.8% 1,790.4 rupees** Pharma co gets approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis** Stock last up 1.7%; top pct gainer on the Nifty Pharma index <span>.NIPHARM</span>, which is down 0.6%** More than 419,000 shares traded, 3.8x the 30-day moving avg** Mean rating of stock is \"hold\"; their median PT is 2,050 rupees - data compiled by LSEG** GLAD fell 3.2% in 2025</p><p> (Reporting by Meenakshi Maidas in Bengaluru)</p><p> ((meenakshi.maidas@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-India's Gland Pharma rises after US FDA approval for drug application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-India's Gland Pharma rises after US FDA approval for drug application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-India's Gland Pharma rises after US FDA approval for drug application</title></head><body><p>** Shares of Gland Pharma <span>GLAD.NS</span> rise as much as 4.8% 1,790.4 rupees** Pharma co gets approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis** Stock last up 1.7%; top pct gainer on the Nifty Pharma index <span>.NIPHARM</span>, which is down 0.6%** More than 419,000 shares traded, 3.8x the 30-day moving avg** Mean rating of stock is \"hold\"; their median PT is 2,050 rupees - data compiled by LSEG** GLAD fell 3.2% in 2025</p><p> (Reporting by Meenakshi Maidas in Bengaluru)</p><p> ((meenakshi.maidas@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00656","symbol_name":"复星国际","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL6N3Y909K:1","article_id":"2601334147","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601334147","pubTimestamp":1767845237,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-India's Gland Pharma rises after US FDA approval for drug application** Shares of Gland Pharma GLAD.NS rise as much as 4.8% 1,790.4 rupees** Pharma co gets approval from the United States Food and Drug Administration  for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis** Stock last up 1.7%; top pct gainer on the Nifty Pharma index .NIPHARM, which is down 0.6%** More than 419,000 shares traded, 3.8x the 30-day moving avg** Mean rating of stock is \"hold\"; their median PT is 2,050 rupees - data compiled by LSEG** GLAD fell 3.2% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00656":"复星国际","BK1230":"工业集团企业"},"translate_title":"美国FDA批准药物申请后，印度Gland Pharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00656":0.9},"content_text":"BUZZ-India's Gland Pharma rises after US FDA approval for drug application** Shares of Gland Pharma GLAD.NS rise as much as 4.8% 1,790.4 rupees** Pharma co gets approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis** Stock last up 1.7%; top pct gainer on the Nifty Pharma index .NIPHARM, which is down 0.6%** More than 419,000 shares traded, 3.8x the 30-day moving avg** Mean rating of stock is \"hold\"; their median PT is 2,050 rupees - data compiled by LSEG** GLAD fell 3.2% in 2025 (Reporting by Meenakshi Maidas in Bengaluru) ((meenakshi.maidas@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601334147","isCrawlerRequest":true}